Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PY314 alone and with Pembrolizumab in Advanced Solid Tumors
NCT04691375Phase 1Terminated
- Sponsor
- ImageneBio
- Start
- Oct 2020
- Primary completion
- Aug 2023
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of py314 in solid tumor (advanced stage), gynecologic cancer, breast cancer and 5 more (4 arms), sponsored by ImageneBio. Primary endpoints: Incidence of Adverse Events at 36 months and Dose Limiting Toxicity at 21 days. Started Oct 2020; status: terminated.
02
Drugs
py314
03
Conditions
solid tumor (advanced stage)gynecologic cancerbreast cancercolorectal cancer (CRC)lung adenocarcinoma
Beyond the preview
Go deeper on NCT04691375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04691375.